Laurel Wealth Advisors (North Carolina)’s Editas Medicine EDIT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
– Sell
-500
Closed -$6K – 563
2022
Q2
$6K Buy
500
+409
+449% +$5.48K ﹤0.01% 423
2022
Q1
$2K Hold
91
– – ﹤0.01% 578
2021
Q4
$2K Hold
91
– – ﹤0.01% 580
2021
Q3
$4K Sell
91
-250
-73% -$13.7K ﹤0.01% 505
2021
Q2
$19K Buy
+341
New +$12.6K ﹤0.01% 382

Other funds holding EDIT

Laurel Wealth Advisors (North Carolina)'s EDIT Position: Q3 2022 in Review

Laurel Wealth Advisors (North Carolina) sold out of Editas Medicine (EDIT) in Q3 2022, closing a stake of 500 shares — an estimated $6K sold.

Laurel Wealth Advisors (North Carolina) first reported a position in EDIT in Q2 2021 and held it in 5 quarters. The position peaked at $19K in Q2 2021. 265 funds tracked by Wall St. Rank hold EDIT as of Q3 2022.

  • Laurel Wealth Advisors (North Carolina) reported no remaining Editas Medicine position as of Q3 2022 after selling out during the quarter.
  • Laurel Wealth Advisors (North Carolina) sold 500 Editas Medicine shares in Q3 2022, an estimated $6K.
  • Laurel Wealth Advisors (North Carolina) first reported a position in Editas Medicine in Q2 2021 and held it in 5 quarters.
  • Laurel Wealth Advisors (North Carolina)'s Editas Medicine position peaked at $19K in Q2 2021.
  • 265 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2022.

Based on Laurel Wealth Advisors (North Carolina)'s 13F filing for Q3 2022, filed 15 Nov 2022.